홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
BLRX
#4853
BioLineRX Ltd
2.385
0
USD
+0.21%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+0.21%
월간 변동
-6.84%
6달 변화
-15.12%
년간 변동율
-15.12%
이전 종가
2.380
0
Open
2.385
0
Bid
Ask
Low
2.385
0
High
2.385
0
양
1
마켓
주식
헬스케어
BLRX
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
Q4, 24
Q4, 25
TTM
Key stats
Total common shares outstanding
3.72 M
4.35 M
—
Valuation ratios
Enterprise value
31.85 M
12.05 M
47.68 M
Price to earnings ratio
—
—
—
Price to sales ratio
—
—
—
Price to cash flow ratio
—
—
—
Price to book ratio
—
—
—
EBITDA 비율에 대한 기업 가치
—
—
—
Profitability ratios
Return on assets %
—
—
—
Return on equity %
—
—
—
Return on invested capital %
—
—
—
Gross margin %
—
—
—
Operating margin %
—
—
—
EBITDA margin %
—
—
—
Net margin %
—
—
—
Liquidity ratios
Quick ratio
—
—
—
Current ratio
—
—
—
Inventory turnover
—
—
—
Asset turnover
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
Debt to equity ratio
—
—
—
Long term debt to total assets ratio
—
—
—
Long term debt to total equity ratio
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
EBIT per share
—
—
—
EBITDA per share
—
—
—
Total debt per share
—
—
—
Cash per share
—
—
—
Net current asset value per share
—
—
—
Tangible book value per share
—
—
—
Working capital per share
—
—
—
Book value per share
—
—
—
BioLineRx Ltd - American Depositary Shares
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
뉴스
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
BioLineRx 3분기 실적 발표: 매출 예상치 대폭 하회
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss
BioLineRx, 예상 뛰어넘는 실적 발표에 7% 이상 상승
BioLineRx shares rise over 7% on better-than-expected earnings
BioLineRx 주가, 파트너사 특허 승인 소식에 상승
BioLineRx stock rises after partner receives key patent allowance
GLIX1 암 치료제, 특허 허가 획득
Hemispherian receives patent allowance for cancer drug GLIX1
암 치료제 핵심 특허 확보 후 BioLineRx 주가 상승
BioLineRx stock rises after securing key patent for cancer treatment